19 December 2018
SUMMARY
- Phase II study in vitiligo, a treatment-resistant disease1
- n=21, patients of Asian ethnicity, darker skin complexion
- Pooled analysis of data collected on all patients who received SCENESSE® with NB-UVB (n=18)
- Six doses of SCENESSE® subcutaneously administered monthly in combination with NB-UVB twice a week
- Repigmentation therapy with SCENESSE® in combination with NB-UVB effective and safety profile maintained: